دورية أكاديمية
Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel.
| العنوان: | Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. |
|---|---|
| المؤلفون: | Brouwer TP; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands, PO Box 9600, 2300 RC., Vahrmeijer AL; Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands, PO Box 9600, 2300 RC. N.F.de_Miranda@lumc.nl. |
| المصدر: | Cellular oncology (Dordrecht) [Cell Oncol (Dordr)] 2021 Apr; Vol. 44 (2), pp. 261-278. Date of Electronic Publication: 2021 Mar 12. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Dordrecht : Springer |
| مواضيع طبية MeSH: | Immunotherapy*, Pancreatic Neoplasms/*immunology , Pancreatic Neoplasms/*therapy, Carcinoma, Pancreatic Ductal/immunology ; Carcinoma, Pancreatic Ductal/pathology ; Carcinoma, Pancreatic Ductal/therapy ; Clinical Trials as Topic ; Humans ; Oncolytic Virotherapy ; Pancreatic Neoplasms/pathology ; Stromal Cells/pathology |
| مستخلص: | Background: Checkpoint blockade immunotherapy has had a significant impact on the survival of a subset of patients with advanced cancers. It has been particularly effective in immunogenic cancer types that present large numbers of somatic mutations in their genomes. To date, all conventional immunotherapies have failed to produce significant clinical benefits for patients diagnosed with pancreatic cancer, probably due to its poor immunogenic properties, including low numbers of neoantigens and highly immune-suppressive microenvironments. Conclusions: Herein, we discuss advances that have recently been made in cancer immunotherapy and the potential of this field to deliver effective treatment options for pancreatic cancer patients. Preclinical investigations, combining different types of therapies, highlight possibilities to enhance anti-tumor immunity and to generate meaningful clinical responses in pancreatic cancer patients. Results from completed and ongoing (pre)clinical trials are discussed. |
| References: | J Clin Oncol. 2015 Apr 20;33(12):1325-33. (PMID: 25584002) Mol Cancer Ther. 2006 May;5(5):1108-16. (PMID: 16731742) J Immunother. 2013 Sep;36(7):382-9. (PMID: 23924790) Trends Cell Biol. 2001 Nov;11(11):S44-51. (PMID: 11684442) N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881) JAMA. 2013 Oct 9;310(14):1473-81. (PMID: 24104372) Semin Cancer Biol. 2012 Aug;22(4):275-81. (PMID: 22313874) Nat Rev Immunol. 2016 Nov 25;16(12):723-740. (PMID: 27885276) N Engl J Med. 2014 Sep 11;371(11):1039-49. (PMID: 25207767) N Engl J Med. 2014 Dec 4;371(23):2189-2199. (PMID: 25409260) Clin Cancer Res. 2019 Sep 15;25(18):5493-5502. (PMID: 31126960) J Immunol. 2006 Sep 1;177(5):3448-60. (PMID: 16920987) Pancreas. 2004 Jan;28(1):38-44. (PMID: 14707728) Nature. 1994 Dec 22-29;372(6508):786-91. (PMID: 7997267) Science. 2011 Mar 25;331(6024):1612-6. (PMID: 21436454) Lancet Oncol. 2019 Oct;20(10):1395-1408. (PMID: 31422028) Int J Cancer. 2011 Mar 1;128(5):1120-8. (PMID: 20473937) Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. (PMID: 30635425) Lancet. 2016 Jul 2;388(10039):73-85. (PMID: 26830752) Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070) World J Oncol. 2019 Feb;10(1):10-27. (PMID: 30834048) Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. (PMID: 31315885) N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128) Gene Ther. 2001 Feb;8(4):308-15. (PMID: 11313805) Cancer Res. 2014 Sep 15;74(18):5057-69. (PMID: 25082815) J Immunol. 2008 Nov 1;181(9):6595-603. (PMID: 18941250) J Clin Oncol. 2001 Jan 1;19(1):145-56. (PMID: 11134207) J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33688022) Cancer Immunol Res. 2017 Feb;5(2):100-105. (PMID: 28062513) J Clin Oncol. 2009 Dec 1;27(34):5763-71. (PMID: 19884534) N Engl J Med. 2009 Nov 5;361(19):1838-47. (PMID: 19890126) Annu Rev Immunol. 2019 Apr 26;37:173-200. (PMID: 30550719) J Clin Oncol. 2015 Jun 10;33(17):1889-94. (PMID: 25667295) J Transl Med. 2018 Feb 6;16(1):23. (PMID: 29409514) Cancer Immunol Immunother. 2011 Oct;60(10):1419-30. (PMID: 21644036) Invest New Drugs. 2018 Feb;36(1):96-102. (PMID: 29119276) Oncotarget. 2017 Dec 31;9(6):6659-6677. (PMID: 29467918) Nat Med. 2019 Jun;25(6):920-928. (PMID: 31086347) Nature. 2017 Jul 13;547(7662):217-221. (PMID: 28678778) J Clin Oncol. 2016 Dec;34(34):4171-4179. (PMID: 27863199) BMC Cancer. 2017 Aug 29;17(1):576. (PMID: 28851316) JAMA Oncol. 2019 Jul 18;:. (PMID: 31318392) Cancer Res. 2017 Aug 1;77(15):4158-4170. (PMID: 28611041) Oncogene. 1999 Jan 28;18(4):1073-80. (PMID: 10023684) Lancet Respir Med. 2020 Jan;8(1):25-33. (PMID: 31575509) Clin Cancer Res. 2007 Apr 1;13(7):2151-7. (PMID: 17404099) Science. 1998 Jan 16;279(5349):349-52. (PMID: 9454332) Front Oncol. 2017 Sep 08;7:195. (PMID: 28944214) Gastroenterology. 2018 Jul;155(1):29-32. (PMID: 29567081) Lancet. 2017 Mar 11;389(10073):1011-1024. (PMID: 28129987) Trends Cancer. 2016 Oct 1;2(1):20-34. (PMID: 26949745) Nature. 2017 Nov 23;551(7681):512-516. (PMID: 29132146) Mol Cancer Ther. 2011 Nov;10(11):2135-45. (PMID: 21903606) Front Immunol. 2018 Sep 25;9:2166. (PMID: 30319627) Cancer Discov. 2019 Aug;9(8):1102-1123. (PMID: 31197017) Cancer Immunol Immunother. 2009 Oct;58(10):1627-34. (PMID: 19221744) Future Oncol. 2018 Jan;14(1):13-22. (PMID: 29235360) Nature. 2015 Feb 26;518(7540):495-501. (PMID: 25719666) Nature. 2017 Jul 13;547(7662):222-226. (PMID: 28678784) Sci Rep. 2017 Nov 13;7(1):15424. (PMID: 29133913) Nat Commun. 2020 Mar 13;11(1):1395. (PMID: 32170083) Nat Commun. 2015 Apr 09;6:6744. (PMID: 25855536) Nat Med. 2016 Aug;22(8):851-60. (PMID: 27376576) Nature. 2016 Mar 3;531(7592):47-52. (PMID: 26909576) Immunity. 2017 Aug 15;47(2):323-338.e6. (PMID: 28813661) J Cell Sci. 2006 Dec 1;119(Pt 23):4803-10. (PMID: 17130294) Clin Cancer Res. 2017 Aug 1;23(15):4429-4440. (PMID: 28348045) Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. (PMID: 28741618) Cancer Res. 2016 May 1;76(9):2525-39. (PMID: 26980767) Clin Cancer Res. 2013 Nov 15;19(22):6286-95. (PMID: 23983255) Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505) Br J Cancer. 2006 Dec 4;95(11):1474-82. (PMID: 17060934) Front Oncol. 2019 Feb 12;9:56. (PMID: 30809507) Ann Surg. 2011 Feb;253(2):328-35. (PMID: 21217520) Nature. 2014 Nov 27;515(7528):563-7. (PMID: 25428504) Semin Oncol. 2012 Jun;39(3):276-86. (PMID: 22595050) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) J Clin Oncol. 2019 May 1;37(13):1062-1069. (PMID: 30817250) Pancreas. 2004 Jan;28(1):e26-31. (PMID: 14707745) Int J Cancer. 2001 May 1;92(3):441-50. (PMID: 11291084) Nat Genet. 2015 Oct;47(10):1168-78. (PMID: 26343385) Cancer Immunol Immunother. 2015 Feb;64(2):149-59. (PMID: 25305035) Oncogene. 2010 Jan 28;29(4):482-91. (PMID: 19881547) Cancer Discov. 2019 Aug;9(8):1022-1035. (PMID: 31164343) Gastroenterology. 2012 Nov;143(5):1375-1384.e5. (PMID: 22819865) J Cell Sci. 1999 Aug;112 ( Pt 16):2677-91. (PMID: 10413676) Cancer Immunol Immunother. 2014 Oct;63(10):1081-91. (PMID: 25099366) Cancer Immunol Res. 2014 Jul;2(7):616-31. (PMID: 24942756) Cancers (Basel). 2018 May 25;10(6):. (PMID: 29799479) Br J Cancer. 2017 Jun 27;117(1):33-40. (PMID: 28588322) Clin Gastroenterol Hepatol. 2008 Oct;6(10):1155-61. (PMID: 18639493) Sci Transl Med. 2014 Sep 17;6(254):254ra128. (PMID: 25232180) Front Immunol. 2018 Nov 08;9:2593. (PMID: 30467505) Immunity. 2013 Apr 18;38(4):729-41. (PMID: 23562161) Cancer Cell. 2012 Mar 20;21(3):418-29. (PMID: 22439937) Immunity. 2016 Jun 21;44(6):1444-54. (PMID: 27332733) Mol Ther Oncolytics. 2016 Apr 13;3:16006. (PMID: 27162934) Front Immunol. 2015 Apr 24;6:187. (PMID: 25964783) J Clin Invest. 2016 Aug 1;126(8):3130-44. (PMID: 27454297) Science. 1996 Oct 18;274(5286):373-6. (PMID: 8832876) BMB Rep. 2013 Mar;46(3):131-8. (PMID: 23527856) Clin Cancer Res. 2015 Oct 1;21(19):4286-93. (PMID: 25977344) J Clin Oncol. 2018 Feb 1;36(4):359-366. (PMID: 29232172) J Clin Oncol. 2017 Oct 20;35(30):3449-3457. (PMID: 28854067) Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. (PMID: 29367431) Gastroenterology. 2017 Jan;152(1):68-74.e2. (PMID: 27856273) Cancer Cell. 2018 Apr 9;33(4):563-569. (PMID: 29634944) Clin Cancer Res. 2013 Oct 15;19(20):5636-46. (PMID: 23873688) Nat Med. 2007 Sep;13(9):1050-9. (PMID: 17704786) Cancer Res. 2010 Apr 15;70(8):3052-61. (PMID: 20388795) Cancer Biol Ther. 2017 Mar 4;18(3):137-141. (PMID: 28267380) Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. (PMID: 28912137) Mol Ther. 2016 Jun;24(6):1150-1158. (PMID: 27039845) Cancer Gene Ther. 2011 Mar;18(3):167-75. (PMID: 21102422) Int J Clin Oncol. 2017 Aug;22(4):726-733. (PMID: 28314962) Gut. 2016 Oct;65(10):1710-20. (PMID: 26156960) Nat Biotechnol. 2020 Mar;38(3):333-342. (PMID: 31932730) Nat Med. 2011 Apr;17(4):500-3. (PMID: 21460848) Clin Cancer Res. 2003 Feb;9(2):555-61. (PMID: 12576418) Cell. 2019 Jun 27;178(1):160-175.e27. (PMID: 31155233) Theranostics. 2018 Oct 6;8(18):5072-5087. (PMID: 30429887) Nature. 2015 Apr 16;520(7547):373-7. (PMID: 25754329) Ann Oncol. 2014 Sep;25(9):1750-1755. (PMID: 24907635) J Exp Med. 2005 Mar 7;201(5):737-46. (PMID: 15753207) Science. 2015 Apr 3;348(6230):74-80. (PMID: 25838376) J Investig Med. 2012 Apr;60(4):643-63. (PMID: 22406516) J Immunother. 2010 Oct;33(8):828-33. (PMID: 20842054) Clin Cancer Res. 2012 Aug 15;18(16):4266-76. (PMID: 22896693) N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) Sci Rep. 2015 Oct 14;5:15179. (PMID: 26462617) Br J Cancer. 2010 Jan 5;102(1):115-23. (PMID: 19997099) Ann Surg. 2016 Sep;264(3):457-63. (PMID: 27355262) J Clin Invest. 2019 Mar 1;129(3):1109-1114. (PMID: 30714987) Nature. 2012 Nov 15;491(7424):399-405. (PMID: 23103869) Sci Transl Med. 2017 Jun 7;9(393):. (PMID: 28592566) Cancer Discov. 2020 Mar;10(3):422-439. (PMID: 31911451) Blood. 2009 Jul 16;114(3):589-95. (PMID: 19349616) Front Immunol. 2019 Oct 29;10:2534. (PMID: 31736961) N Engl J Med. 2017 Oct 12;377(15):1409-1412. (PMID: 29020592) Cancer Immunol Immunother. 2020 Mar;69(3):355-364. (PMID: 31893287) Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592) Br J Cancer. 2013 Mar 5;108(4):914-23. (PMID: 23385730) J Cell Commun Signal. 2007 Sep;1(2):85-90. (PMID: 18481199) Clin Cancer Res. 2006 Nov 15;12(22):6737-47. (PMID: 17121894) Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. (PMID: 8421711) N Engl J Med. 2010 Jul 29;363(5):411-22. (PMID: 20818862) N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490) J Exp Med. 2011 Mar 14;208(3):469-78. (PMID: 21339327) Gastroenterology. 2012 Oct;143(4):1095-107.e2. (PMID: 22750462) J Immunother. 2015 Jan;38(1):1-11. (PMID: 25415283) Cancer Sci. 2012 Apr;103(4):739-46. (PMID: 22320398) Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. (PMID: 28660319) Br J Cancer. 2018 Nov;119(10):1208-1214. (PMID: 30318515) Nat Med. 1997 Jun;3(6):639-45. (PMID: 9176490) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Int J Cancer. 2013 Aug 1;133(3):624-36. (PMID: 23364915) Eur J Cancer. 2019 Jan;107:124-132. (PMID: 30562710) Int J Cancer. 2017 Feb 15;140(4):973-982. (PMID: 27861852) Cancer Gene Ther. 2019 Sep;26(9-10):268-281. (PMID: 30467340) Cancer Gene Ther. 2005 Sep;12(9):725-36. (PMID: 15818382) Curr Opin Oncol. 2013 Nov;25(6):637-45. (PMID: 24076584) N Engl J Med. 2018 Feb 1;378(5):449-459. (PMID: 29385376) Sci Transl Med. 2020 Mar 18;12(535):. (PMID: 32188726) Science. 2015 Apr 3;348(6230):62-8. (PMID: 25838374) J Immunol Res. 2014;2014:879897. (PMID: 24741628) J Cell Biol. 2012 Feb 20;196(4):395-406. (PMID: 22351925) Science. 2008 Sep 26;321(5897):1801-6. (PMID: 18772397) BMC Cancer. 2018 May 25;18(1):596. (PMID: 29801474) Lancet Oncol. 2014 Jul;15(8):829-40. (PMID: 24954781) Cancer Sci. 2017 Jan;108(1):73-80. (PMID: 27783849) J Exp Med. 2006 May 15;203(5):1259-71. (PMID: 16636135) Clin Cancer Res. 2015 Aug 1;21(15):3561-8. (PMID: 25695692) Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308) JAMA Oncol. 2017 Jun 1;3(6):841-849. (PMID: 27441411) N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140) Nat Rev Immunol. 2018 Oct;18(10):635-647. (PMID: 30057419) Front Immunol. 2019 Jul 31;10:1799. (PMID: 31417566) J Clin Oncol. 2017 Oct 20;35(30):3382-3390. (PMID: 28767289) Clin Cancer Res. 2016 Jun 15;22(12):2848-54. (PMID: 26813359) J Immunol. 2005 Jun 15;174(12):7516-23. (PMID: 15944250) |
| معلومات مُعتمدة: | European Commission H2020 MSCA-ETN grant under proposal number 675743 (project acronym: ISPIC) FP7 People: Marie-Curie Actions; European Union's Horizon 2020 research and innovation programme (grant agreement No. 852832) H2020 European Research Council |
| فهرسة مساهمة: | Keywords: Checkpoint blockade; Immunotherapy; Microenvironment; PDAC; Pancreatic ductal adenocarcinoma; Stroma; combination therapies |
| تواريخ الأحداث: | Date Created: 20210312 Date Completed: 20211006 Latest Revision: 20211006 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7985121 |
| DOI: | 10.1007/s13402-021-00587-z |
| PMID: | 33710604 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2211-3436 |
|---|---|
| DOI: | 10.1007/s13402-021-00587-z |